thromboembolic — TargetMol Chemicals

Search Result

Search Results for " thromboembolic "

Compounds

Cat No.	Product Name	Synonyms	Targets
T3536	AZD1283		P2Y Receptor
	AZD1283 is an effective P2Y12 receptor antagonist (EC50: 3.0 ug/kg/min, binding IC50: 11 nM). AZD1283 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithromboti...		P2Y Receptor
T2368	Edoxaban Tosylate Monohydrate	DU-176b,DU-176b tosylate Monohydrate,Lixiana,Edoxaban	Factor Xa , Thrombin
	Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.		Factor Xa , Thrombin
T3781	Jujuboside B		Others
	Jujuboside B has potent inhibitory effects on collagen-, thrombin-, AA-, and ADP-induced aggregation, and also exhibits superior protection on the thromboembolic model.		Others
T77124	Osocimab	BAY 1213790	FXR
	Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an i...		FXR
T2368L	Edoxaban	Lixiana	Factor Xa , Thrombin
	Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is a...		Factor Xa , Thrombin
T70184	YM-60828 dihydrochloride
	YM-60828 dihydrochloride is a Factor Xa (FXa) inhibitor and anticoagulant used in the treatment of venous thromboembolic disease.
T71096	GCC-4401C methanesulfonate
	GCC-4401C methanesulfonate is a factor Xa inhibitor similar to rivaroxaban that is currently under development for venous thromboembolic disease (VTE).
T71362	GCC-4401C free base
	GCC-4401C free base is a factor Xa inhibitor similar to rivaroxaban that is currently under development for venous thromboembolic disease (VTE).
T70233	Efegatran HCl
	Efegatran, also known as GYKI-14166, RGH-2958 and LY294468, a thrombin inhibitor which is being developed by IVAX for the potential treatment of thromboembolic disorders.
T60576	Cyproheptadine
	Cyproheptadine is a potent and orally active antagonist of the 5-HT 2A receptor. Cyproheptadine has antidepressant and antiserotonergic effects. Cyproheptadine also has antiplatelet and thromboprotective activities that ...
T63239	FXa-IN-1
	FXa-IN-1 is an FXa inhibitor with an IC50 value of 3 nM and a Ki value of 0.7 nM that exhibits good oral bioavailability and half-life (in vivo) and can be used to study thromboembolic diseases.
T76894	Abelacimab
	Abelacimab (MAA868), a fully human IgG1 monoclonal antibody, targets and binds with high affinity to FXI's catalytic structural domain. This interaction ensures FXI remains in its zymogen form, effectively inhibiting act...
T11100	DS-1040 Tosylate		Others
	DS-1040 Tosylate is an oral active, selective thrombolytic inhibitor with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa, is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhi...		Others
T64126	Edoxaban hydrochloride
	Edoxaban (DU-176b) hydrochloride is a potent, selective, orally active, direct inhibitor of Factor Xa (FXa), acting on human free FXa (Ki: 0.561 nM) and thrombinogenase (Ki: 2.98 nM). Edoxaban hydrochloride is more than ...
T64099	FXIa-IN-9
	FXIa-IN-9 (compound 3f) is a potent, selective inhibitor of FXIa, demonstrating strong binding affinity through hydrogen bond formation (human FXIa K i : 0.17 nM, rabbit FXIa K i : 0.5 nM). It exhibits anticoagulant prop...